Isto Biologics Acquires Allograft Firm TheraCell

Isto Biologics, a surgical-based orthobiologic regeneration tech and cell-based therapy firm, has acquired allograft solution company TheraCell. The deal will strengthen Isto’s focus on surgical and clinical care procedures in spine, orthopedics, and sports medicine.
 
It will specifically expand Isto’s growing orthopedic graft business and introduce the TheraFuze DBF (demineralized bone fiber) tech to Isto’s Influx line.
 
“We are pleased that Isto, a leader in allogeneic spine solutions, has recognized the value and importance of what we have developed and are excited about how their patient-centric, outcomes-focused commercial and clinical teams will rapidly accelerate the surgical adoption of the products and technology that we are so passionate about,” TheraCell co-founder and CEO Bradley Patt, Ph.D. told the press.
 
“We are thrilled to add TheraCell’s unmatched technology to our market leading biologics portfolio,” added Don Brown, CEO of Isto Biologics. “TheraCell has excelled in developing advanced bone integrating, anchoring, and bridging technologies for spinal repair for over a decade including their award winning TheraFuze DBF Fiber Anchor and TheraFuze DBF Fiber Bag.”